Updated:
Longevity Vision Fund
Sergey Young's Longevity Vision Fund deploys $100M from multi-family capital into AI-driven diagnostics, biotech, and age-reversal science.
Longevity Vision Fund
Longevity Vision Fund was established in 2018 by Sergey Young, a longevity evangelist and former executive in the telecommunications sector who transitioned into health technology investing. The fund operates as a multi-family office vehicle, pooling capital from high-net-worth families aligned with the thesis that extending healthy human lifespan represents the most significant investment opportunity of the coming decades. Young, who serves as Chief Executive Officer, anchored the fund's identity through his public advocacy for accessible longevity technology and his role as an XPRIZE Foundation board member. The firm deploys capital primarily through direct venture and growth-stage investments across biotechnology, AI-driven diagnostics, medical devices, and therapeutic platforms. The strategy targets companies commercializing breakthroughs in early disease detection, gene therapy, and age-reversal science. Geographic coverage spans North America and Europe, with known portfolio exposure to firms including Insilico Medicine, a leader in AI-powered drug discovery, and Gero, which applies physics-based models to aging research. The fund structures its commitments as direct equity stakes, avoiding traditional fund-of-funds architecture in favor of concentrated, thesis-aligned positions. With a disclosed deployment capacity of $100 million, the fund operates from its primary office in San Francisco and maintains a network of affluent family co-investors rather than a large internal professional staff. The firm's footprint extends through satellite offices in Palo Alto, Santa Monica, and New York, reflecting the distributed nature of its family wealth network. In parallel, Young has built the 'Longevity Vision' media and content platform to surface deal flow and educate potential co-investors, creating a proprietary pipeline that blends public thought leadership with private capital deployment. What structurally differentiates Longevity Vision Fund from generalist venture firms is its singular thematic mandate — the fund will not invest outside the longevity ecosystem. This constraint functions as both a sourcing advantage and a concentration risk: portfolio companies align fully with founder expertise and network, but the absence of diversification across unrelated sectors demands exceptional deal selection within a narrow aperture. The governance structure centers on Young as final investment authority with input from participating family offices on a deal-by-deal basis, a model that prioritizes thesis purity over committee-driven breadth.
General information
Firm type
Multi Family Office
Year founded
2018
AUM
$100M – $250M (Altss estimate)
Location
Region
North America
Country
United States
City
San Francisco
Corporate office
San Francisco, CA, United States
Additional offices
Palo Alto, CA · Santa Monica, CA · New York, NY
Principals
Sergey Young
Founder and Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Longevity Vision Fund?
Sergey Young, the fund's founder and CEO, serves as the primary investment decision-maker. He evaluates opportunities based on scientific merit and alignment with the core longevity thesis, drawing on input from participating family offices on individual deals. Young's background bridges technology commercialization and longevity advocacy, including his role on the XPRIZE Foundation board.
How does Longevity Vision Fund source proprietary deal flow?
The fund sources opportunities through Sergey Young's extensive public platform — including his book 'The Science and Technology of Growing Young' and the Longevity Vision media content series — which attracts inbound founder interest. Additionally, the annual Longevity Investors Conference, held in Gstaad, Switzerland, convenes a curated group of founders, scientists, and family offices for relationship-building and co-investment origination.
Is Longevity Vision Fund a single-family office or does it operate more like a venture firm?
It operates as a multi-family office venture fund. Capital comes from a network of high-net-worth families rather than a single source of wealth, but the investment structure mimics a thematically concentrated venture growth fund — direct equity stakes in portfolio companies, no fund-of-funds layer, and a strict sector mandate. The fund does not disclose its underlying family participants publicly.
Does Longevity Vision Fund participate in fund commitments or only direct deals?
The fund focuses almost exclusively on direct investments into operating companies, according to its public communications. There is no evidence of significant commitments to external venture funds as limited partners. This direct approach gives it more control and alignment with its thesis but concentrates risk in a smaller number of positions.
Which sectors does Longevity Vision Fund explicitly avoid?
The fund draws a hard boundary around non-longevity sectors. It will not invest in generalist software, consumer goods, fintech, or industrial technology unless there is a direct application to extending healthy human lifespan. This thesis purity means passing on otherwise attractive opportunities that fall outside the aging and healthspan intersection.
Where does the underlying wealth come from?
Longevity Vision Fund does not publicly disclose the specific wealth origins of its family office limited partners. The fund pools capital from multiple high-net-worth families who share Sergey Young's longevity investment thesis. Young himself transitioned into longevity investing from the telecommunications sector, where he held executive roles before founding the fund in 2018.
What is Longevity Vision Fund's posture on co-investments alongside external GPs?
The fund actively encourages co-investment from its network of family offices and external investors aligned with the longevity thesis. Its annual investor conference is explicitly designed to facilitate these arrangements. However, it structures its own commitments as direct investments, not as a co-investment vehicle alongside traditional general partners in multi-strategy funds.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: